Skip to main content

Table 2 Demographics among patients with elevated depression symptoms at baseline (and at least 2 PHQ-9 scores in the first 6 months)

From: Factors associated with response and remission from depression at 6-months of treatment in a retrospective cohort treated within an integrated care program

Demographics (N = 615) N (%)
Gender
 Male 211 (34.31)
 Female 404 (65.69)
Ethnicity
 Hispanic/Latino 99 (16.10)
 Not Hispanic/Latino 458 (74.47)
 Missing 58 (9.43)
Race
 White/Caucasian 354 (57.56)
 Asian 54 (8.78)
 Black/African American 35 (5.69)
 Two or More Races 19 (3.09)
 Other/Unknowna 153 (24.88)
Marital Status
 Married/Domestic Partner 209 (33.98)
 Previously Married/Domestic Partner 40 (6.50)
 Single 348 (56.59)
 Otherb 18 (2.93)
Age
 Age at Baseline, Mean (SD) 40.51 (14.82)
Baseline Depression Symptoms
 PHQ-9 Score, Mean (SD) 15.87 (4.56)
Suicidal Ideation at Baseline
 Yesc 248 (40.33)
Treatment Response by 6-month Follow-up
 PHQ-9 Score < 5 100 (16.26)
 PHQ-9 Score < 10 289 (46.99)
 Reduction in PHQ-9 Score ≥ 6 277 (45.04)
Other Clinical Symptoms at Baselined,e
 GAD-7 Score ≥ 10 434 (70.57)
 AUDIT-C Score ≥ 3f 228 (37.07)
 DAST-10 Score ≥ 3g 64 (10.41)
 PCL Score > 50 174 (28.29)
Number of Treatment Sessions
 Total, Mean (SD)h 7.29 (4.04)
 With a Physician, Mean (SD) 2.81 (2.02)
 With a Therapist, Mean (SD) 3.91 (4.33)
  1. a “Other/Unknown” includes: “American Indian or Alaska Native”, “Native Hawaiian or Other Pacific Islander”, “Other”, “Unknown”
  2. b “Other” includes: Life Partner, Significant Other, Unknown, Other, Missing
  3. c Includes any endorsement on PHQ-9 item 9 except “Not at all”
  4. d Percentage is out of the total N = 615, though some patients had a missing value on the AUDIT-C, DAST-10, and/or PCL
  5. e For the purposes of the analyses, patients who did not meet screening criteria for a given measure were given a “No” on meeting a clinical threshold (rather than given a missing status)
  6. f Clinical cutoff is ≥3 for females, ≥ 4 for males
  7. g Cutoff ≥3 indicates at least “moderate” symptoms; patients were only administered the DAST-10 if they screened positive on the 1-item screener
  8. h Includes visits that did not indicate a provider type